Piramal Pharma Limited
Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC).Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitionsand various organic…
What Piramal files
- Others47
- Investor Meet43
- Important30
- Updates25
- Board Meeting11
- PPTs8
Piramal Pharma reported ₹8,869 Cr revenue, ₹1,135 Cr EBITDA, and a ₹325.94 Cr net loss amid market headwinds. The company invested ₹890 Cr and US$90M in advanced therapies, boosting growth prospects. Operational excellence drove 22.6% emissions cut & 41% renewable energy, with advancing digital transformation.
Piramal Pharma approved acquiring an additional 41% stake in Yapan Bio, a CDMO for vaccines and biologics. This increases PPL's holding to ~74%, making Yapan Bio a subsidiary and strengthening PPL's CDMO capabilities.
Piramal Pharma's Ahmedabad facilities have largely resumed operations after temporary suspension due to heavy rainfall. The company expects no material impact on its operations or financial performance and has initiated an insurance claim.
Piramal Pharma temporarily suspended operations at its Ahmedabad facilities due to heavy rainfall and flooding. Employees are safe, and normalization is expected soon. These facilities represent <3% of consolidated revenue, and assets are insured, limiting major financial impact.
Piramal Pharma's FY26 sustainability report noted a ₹1.15 Cr penalty for environmental compliance and one voluntary Prazosin product recall. The company demonstrated strong ESG performance, utilizing 40.9% renewable energy, achieving 95% waste recovery, and recycling 191,887 kL of water across global sites.